Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial.

Tanton C, Weiss HA, Rusizoka M, Legoff J, Changalucha J, Baisley K, Mugeye K, Everett D, Belec L, Clayton TC, Ross DA, Hayes RJ, Watson-Jones D.

J Infect Dis. 2010 May 1;201(9):1285-97. doi: 10.1086/651696.

2.

Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa.

Delany S, Mlaba N, Clayton T, Akpomiemie G, Capovilla A, Legoff J, Belec L, Stevens W, Rees H, Mayaud P.

AIDS. 2009 Feb 20;23(4):461-9. doi: 10.1097/QAD.0b013e32831db217.

3.

Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial.

Mayaud P, Legoff J, Weiss HA, Grésenguet G, Nzambi K, Bouhlal H, Frost E, Pépin J, Malkin JE, Hayes RJ, Mabey DC, Bélec L; ANRS 1212 Study Group.

J Infect Dis. 2009 Jul 15;200(2):216-26. doi: 10.1086/599991.

PMID:
19530940
4.

High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.

Perti T, Saracino M, Baeten JM, Johnston C, Diem K, Ocbamichael N, Huang ML, Selke S, Magaret A, Corey L, Wald A.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):201-8. doi: 10.1097/QAI.0b013e3182928eea.

5.

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, Mujugira A, Baeten JM, Mullins JI, Hughes JP, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Stevens W, Campbell MS, Thomas KK, Coombs RW, Morrow R, Whittington WL, McElrath MJ, Barnes L, Ridzon R, Corey L; Partners in Prevention HSV/HIV Transmission Study Team.

N Engl J Med. 2010 Feb 4;362(5):427-39. doi: 10.1056/NEJMoa0904849. Epub 2010 Jan 20.

6.

Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.

Nagot N, Ouédraogo A, Foulongne V, Konaté I, Weiss HA, Vergne L, Defer MC, Djagbaré D, Sanon A, Andonaba JB, Becquart P, Segondy M, Vallo R, Sawadogo A, Van de Perre P, Mayaud P; ANRS 1285 Study Group.

N Engl J Med. 2007 Feb 22;356(8):790-9.

7.

A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers.

Cowan FM, Pascoe SJ, Barlow KL, Langhaug LF, Jaffar S, Hargrove JW, Robinson NJ, Bassett MT, Wilson D, Brown DW, Hayes RJ.

Sex Transm Infect. 2008 Dec;84(7):548-53. doi: 10.1136/sti.2008.031153. Epub 2008 Aug 6.

PMID:
18684855
8.

Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes.

LeGoff J, Weiss HA, Gresenguet G, Nzambi K, Frost E, Hayes RJ, Mabey DC, Malkin JE, Mayaud P, Belec L.

AIDS. 2007 Jul 31;21(12):1569-78.

PMID:
17630552
9.

Effect of herpes simplex suppression on incidence of HIV among women in Tanzania.

Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K, Tanton C, Ross D, Everett D, Clayton T, Balira R, Knight L, Hambleton I, Le Goff J, Belec L, Hayes R; HSV trial team; Steering and Data Monitoring Committees.

N Engl J Med. 2008 Apr 10;358(15):1560-71. doi: 10.1056/NEJMoa0800260. Epub 2008 Mar 12. Erratum in: N Engl J Med. 2010 Apr 15;362(15):1450.

10.

Self-collected genital swabs compared with cervicovaginal lavage for measuring HIV-1 and HSV-2 and the effect of acyclovir on viral shedding.

McNicholl JM, Leelawiwat W, Whitehead S, Hanson DL, Evans-Strickfaden T, Cheng CY, Chonwattana W, Mueanpai F, Kittinunvorakoon C, Markowitz L, Dunne EF.

Int J STD AIDS. 2017 Mar;28(4):372-379. doi: 10.1177/0956462416650123. Epub 2016 Jul 10.

11.

Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial.

Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC, Foulongne V, Sanon A, Andonaba JB, Segondy M, Mayaud P, Van de Perre P.

AIDS. 2006 Nov 28;20(18):2305-13.

PMID:
17117016
12.

Effect of HSV-2 suppressive therapy on genital tract HIV-1 RNA shedding among women on HAART: a pilot randomized controlled trial.

Nijhawan AE, Delong AK, Chapman S, Rana A, Kurpewski J, Ingersoll J, Caliendo AM, Cu-Uvin S.

Infect Dis Obstet Gynecol. 2012;2012:868526. doi: 10.1155/2012/868526. Epub 2012 Feb 28.

13.

Patterns of herpes simplex virus shedding over 1 month and the impact of acyclovir and HIV in HSV-2-seropositive women in Tanzania.

Tanton C, Weiss HA, LeGoff J, Changalucha J, Clayton TC, Ross DA, Belec L, Hayes RJ, Watson-Jones D.

Sex Transm Infect. 2011 Aug;87(5):406-11. doi: 10.1136/sti.2010.048496. Epub 2011 Jun 8.

14.

Correlates of HIV-1 genital shedding in Tanzanian women.

Tanton C, Weiss HA, Le Goff J, Changalucha J, Rusizoka M, Baisley K, Everett D, Ross DA, Belec L, Hayes RJ, Watson-Jones D.

PLoS One. 2011 Mar 1;6(3):e17480. doi: 10.1371/journal.pone.0017480.

15.

High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.

Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C.

J Infect Dis. 2011 Dec 15;204(12):1912-7. doi: 10.1093/infdis/jir649. Epub 2011 Oct 12.

16.

Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial.

Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Casapia M, Ortiz A, Fuchs J, Buchbinder S, Koblin B, Zwerski S, Rose S, Wang J, Corey L; HPTN 039 Protocol Team.

Lancet. 2008 Jun 21;371(9630):2109-19. doi: 10.1016/S0140-6736(08)60920-4.

17.

Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand.

Dunne EF, Whitehead S, Sternberg M, Thepamnuay S, Leelawiwat W, McNicholl JM, Sumanapun S, Tappero JW, Siriprapasiri T, Markowitz L.

J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):77-83. doi: 10.1097/QAI.0b013e3181831832.

PMID:
18667923
18.

Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.

Mujugira A, Magaret AS, Celum C, Baeten JM, Lingappa JR, Morrow RA, Fife KH, Delany-Moretlwe S, de Bruyn G, Bukusi EA, Karita E, Kapiga S, Corey L, Wald A; Partners in Prevention HSV/HIV Transmission Study Team.

J Infect Dis. 2013 Nov 1;208(9):1366-74. doi: 10.1093/infdis/jit333. Epub 2013 Jul 30.

19.

Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.

Kim HN, Wang J, Hughes J, Coombs R, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Fuchs J, Eshleman SH, Khaki L, McMahon MA, Siliciano RF, Wald A, Celum C.

J Infect Dis. 2010 Sep 1;202(5):734-8. doi: 10.1086/655662.

20.

Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.

Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Zuñiga R, Magaret AS, Wald A, Corey L, Celum C.

J Infect Dis. 2007 Nov 15;196(10):1500-8. Epub 2007 Oct 31.

PMID:
18008230

Supplemental Content

Support Center